We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





First-Ever Saliva-Based COVID and Influenza Combo Test to Screen for Coronavirus and Flu Infections

By LabMedica International staff writers
Posted on 26 Aug 2020
Researchers are developing a potential coronavirus and influenza combo saliva-based test that would indicate if an individual has been infected by COVID-19, the flu, or neither, according to a report on NJ.com.

The research is being conducted at Rutgers University’s (New Brunswick, NJ, USA) RUCDR Infinite Biologics which had recently developed one of the first saliva-based coronavirus tests in the US. More...
The researchers hope to receive approval for the coronavirus and influenza combo saliva test by the fall in time for the flu season, marking a crucial development as both the viruses share similar characteristics and symptoms.

The coronavirus and influenza combo saliva-based test has a preservation agent that mixes with the saliva and chemically stabilizes the ribonucleic acid extracted from the sample. The preservation agent also renders the virus inactive, making it safer to handle in the lab. Andrew Brooks, chief operating officer and director of technology development at RUCDR, told NJ.com that the lab was working on pooling strategies for a screening application, as well as studying how effective its current test would be in an asymptomatic population. The lab is hoping for continued developments, along with the coronavirus and flu combo test, before the end of 2020.

“There are other companies working on different panels, but this would be the first saliva-based COVID and influenza test,” Brooks said. “We’re gearing up, and we would like for it to be ready by the start of the flu season. Maybe even earlier. We’re not going to delay getting this.”

Related Links:
Rutgers University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Test
Epithod616 COVID-19 Ag
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.